JP2009510068A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009510068A5 JP2009510068A5 JP2008533471A JP2008533471A JP2009510068A5 JP 2009510068 A5 JP2009510068 A5 JP 2009510068A5 JP 2008533471 A JP2008533471 A JP 2008533471A JP 2008533471 A JP2008533471 A JP 2008533471A JP 2009510068 A5 JP2009510068 A5 JP 2009510068A5
- Authority
- JP
- Japan
- Prior art keywords
- direct compression
- tablet
- active ingredient
- granulation
- melt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000007907 direct compression Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000007909 melt granulation Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 1
- 229960003105 Metformin Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Description
製薬業者は迅速な加工時間および経費の利点のために、湿式または乾式造粒法よりも直接圧縮技術の使用を好む。しかしながら通常直接圧縮は、薬物または活性成分が薬学的に許容される錠剤を形成するために要求される物理的特性を有するこれらの状況に限定される。しかしながら直接圧縮法を使用できる前に、多くの成分が必要な特性を有していないので、しばしば一つまたはそれより多い賦形剤を活性成分と組み合わせなければならない。製剤に添加される各賦形剤は最終製品の錠剤の大きさを増すので、製造者は、直接圧縮法の使用をしばしば圧縮錠剤あたり低用量の活性成分を含有する製剤に限定される。 Pharmaceutical companies prefer the use of direct compression techniques over wet or dry granulation because of the advantages of rapid processing time and cost. However, direct compression usually is limited to those situations where the drug or active ingredient has the physical properties required to form a pharmaceutically acceptable tablet. However, before many direct compression methods can be used, often one or more excipients must be combined with the active ingredient since many ingredients do not have the necessary properties. Since each excipient added to the formulation increases the tablet size of the final product, the manufacturer is restricted to the use of direct compression often manufactured agent containing the active ingredient per compressed tablet low doses.
メトホルミン顆粒が湿式造粒により水またはエタノール、イソプロパノール、酢酸エチル、グリコフロール、プロピレングリコールのような有機溶媒から選択される溶媒を用いて生成される本明細書で記載されるような錠剤または医薬組成物。
メトホルミン顆粒が溶融造粒により生成される本明細書で記載されるような錠剤または医薬組成物。溶融造粒過程は「Hot-melt extrusion Technique」: A Review;Iranian Journal of Pharmaceutical Research 3:3-16(2004);Rina Chokshi et al. または総説Joerg Breitenbach 「Melt extrusion: from process to drug delivery technology」: European Journal of Pharmaceutics and Biopharmaceutics 54:107-117(2002)(双方を出典明示により本明細書の一部とする)のような多くの出版物に記載されている。
Water or ethanol Metohorumi emissions granule is by wet granulation, isopropanol, ethyl acetate, glycofurol, tablets such as described herein that is produced by using a solvent selected from organic solvents such as propylene glycol or Pharmaceutical composition.
A tablet or pharmaceutical composition as described herein wherein metformin granules are produced by melt granulation. Melt granulation process is "Hot-melt extrusion Technique": A Review; Iranian Journal of Pharmaceutical Research 3: 3-16 (2004); Rina Chokshi et al. Or review Joerg Breitenbach "Melt extrusion: from process to drug delivery technology" : Published in many publications such as the European Journal of Pharmaceutics and Biopharmaceutics 54: 107-117 (2002), both of which are hereby incorporated by reference.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72262405P | 2005-09-29 | 2005-09-29 | |
| US60/722,624 | 2005-09-29 | ||
| PCT/US2006/037198 WO2007041053A2 (en) | 2005-09-29 | 2006-09-25 | Formulation comprising metformin and vildagli ptin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013146163A Division JP2013241429A (en) | 2005-09-29 | 2013-07-12 | New formulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009510068A JP2009510068A (en) | 2009-03-12 |
| JP2009510068A5 true JP2009510068A5 (en) | 2009-11-05 |
| JP5415762B2 JP5415762B2 (en) | 2014-02-12 |
Family
ID=37876819
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008533471A Active JP5415762B2 (en) | 2005-09-29 | 2006-09-25 | New formulation |
| JP2013146163A Withdrawn JP2013241429A (en) | 2005-09-29 | 2013-07-12 | New formulation |
| JP2015201008A Active JP6270793B2 (en) | 2005-09-29 | 2015-10-09 | New formulation |
| JP2017202104A Withdrawn JP2018052945A (en) | 2005-09-29 | 2017-10-18 | Novel formulations |
| JP2019042906A Withdrawn JP2019131567A (en) | 2005-09-29 | 2019-03-08 | Novel formulation |
| JP2020151616A Active JP7194153B2 (en) | 2005-09-29 | 2020-09-09 | New formulation |
| JP2022065829A Pending JP2022106763A (en) | 2005-09-29 | 2022-04-12 | Novel formulations |
| JP2023193231A Pending JP2024028702A (en) | 2005-09-29 | 2023-11-13 | New formulation |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013146163A Withdrawn JP2013241429A (en) | 2005-09-29 | 2013-07-12 | New formulation |
| JP2015201008A Active JP6270793B2 (en) | 2005-09-29 | 2015-10-09 | New formulation |
| JP2017202104A Withdrawn JP2018052945A (en) | 2005-09-29 | 2017-10-18 | Novel formulations |
| JP2019042906A Withdrawn JP2019131567A (en) | 2005-09-29 | 2019-03-08 | Novel formulation |
| JP2020151616A Active JP7194153B2 (en) | 2005-09-29 | 2020-09-09 | New formulation |
| JP2022065829A Pending JP2022106763A (en) | 2005-09-29 | 2022-04-12 | Novel formulations |
| JP2023193231A Pending JP2024028702A (en) | 2005-09-29 | 2023-11-13 | New formulation |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US20080227825A1 (en) |
| EP (1) | EP1948149B2 (en) |
| JP (8) | JP5415762B2 (en) |
| KR (2) | KR101595169B1 (en) |
| CN (1) | CN101277688B (en) |
| AR (1) | AR055441A1 (en) |
| AT (1) | ATE533481T1 (en) |
| AU (1) | AU2006297444B2 (en) |
| BR (1) | BRPI0616694B8 (en) |
| CA (1) | CA2623011C (en) |
| CY (1) | CY1112305T1 (en) |
| DK (1) | DK1948149T4 (en) |
| EC (1) | ECSP088318A (en) |
| ES (1) | ES2377572T5 (en) |
| GT (1) | GT200600426A (en) |
| HK (1) | HK1121372A1 (en) |
| IL (1) | IL189856A (en) |
| JO (2) | JOP20180109A1 (en) |
| MA (1) | MA29854B1 (en) |
| MY (1) | MY144975A (en) |
| NO (2) | NO346101B1 (en) |
| NZ (1) | NZ566430A (en) |
| PE (1) | PE20070583A1 (en) |
| PH (1) | PH12014500051A1 (en) |
| PL (1) | PL1948149T5 (en) |
| PT (1) | PT1948149E (en) |
| RU (1) | RU2483716C9 (en) |
| SG (4) | SG10201401826TA (en) |
| SI (1) | SI1948149T2 (en) |
| TN (1) | TNSN08146A1 (en) |
| TW (1) | TWI389685B (en) |
| WO (1) | WO2007041053A2 (en) |
| ZA (1) | ZA200801773B (en) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (en) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| AU2006244213B2 (en) * | 2005-05-10 | 2010-05-13 | Novartis Ag | Extrusion process for making compositions with poorly compressible therapeutic compounds |
| DE102005035891A1 (en) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals |
| JOP20180109A1 (en) * | 2005-09-29 | 2019-01-30 | Novartis Ag | New Formulation |
| EP1962827A4 (en) | 2005-12-16 | 2011-02-16 | Merck Sharp & Dohme | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
| MX2008014024A (en) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Polymorphs. |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20080251A1 (en) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | USES OF DPP IV INHIBITORS |
| CL2008002427A1 (en) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Pharmaceutical composition comprising 1-chloro-4- (bd-glucopyranos-1-yl) -2- [4 - ((s) -tetrahydrofuran-3-yloxy) benzyl] -benzene combined with 1 - [(4-methylquinazolin- 2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -aminopiperidin-1-yl) xanthine; and its use to treat type 2 diabetes mellitus. |
| FR2928836B1 (en) * | 2008-03-21 | 2011-08-26 | Servier Lab | SECURE GALENIC FORM FOR MODIFIED RELEASE OF THE ACTIVE INGREDIENT |
| PE20091730A1 (en) * | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | FORMULATIONS INVOLVING A DPP4 INHIBITOR |
| AU2014262269B2 (en) * | 2008-04-03 | 2017-02-02 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
| BRPI0916997A2 (en) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | DPP-4 INHIBITOR AND ITS USE |
| UY32030A (en) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN" |
| US8513264B2 (en) | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| KR101054911B1 (en) | 2008-10-17 | 2011-08-05 | 동아제약주식회사 | Pharmaceutical composition for the prevention and treatment of diabetes or obesity containing a compound that inhibits the activity of dipeptidyl peptidase-IV and other anti-diabetic or anti-obesity drugs as an active ingredient |
| GB2465796A (en) * | 2008-12-01 | 2010-06-02 | Bee Kang Tan | Metformin for the therapeutic use of conditions with raised serum amyloid A levels |
| CN107011345A (en) | 2008-12-23 | 2017-08-04 | 勃林格殷格翰国际有限公司 | The salt form of organic compound |
| AR074990A1 (en) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY |
| AU2010212867B2 (en) | 2009-02-13 | 2013-05-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof |
| EA034049B1 (en) * | 2009-07-31 | 2019-12-23 | КРКА, д.д., НОВО МЕСТО | Granulate comprising vildagliptin, process of preparation thereof and pharmaceutical composition |
| EP2295083A1 (en) | 2009-09-15 | 2011-03-16 | Ratiopharm GmbH | Pharmaceutical composition comprising active agents metformin and sitagliptin or vildagliptin |
| JP5758900B2 (en) | 2009-09-30 | 2015-08-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Process for the preparation of glucopyranosyl-substituted benzylbenzene derivatives |
| KR101763659B1 (en) * | 2009-10-02 | 2017-08-01 | 베링거 인겔하임 인터내셔날 게엠베하 | Pharmaceutical compositions comprising BI-1356 and metformin |
| US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| IN2012DN03271A (en) * | 2009-10-23 | 2015-10-23 | Merck Sharp & Dohme | |
| EP3646859A1 (en) | 2009-11-27 | 2020-05-06 | Boehringer Ingelheim International GmbH | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| KR20120105035A (en) * | 2009-12-22 | 2012-09-24 | 노파르티스 아게 | Formulation comprising 1h-quinazoline-2,4-dione ampa receptor antagonists, in the form of immediate release tablets and preparation thereof |
| AU2011249722B2 (en) | 2010-05-05 | 2015-09-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
| BR112012032579B1 (en) | 2010-06-24 | 2021-05-11 | Boehringer Ingelheim International Gmbh | use of linagliptin and pharmaceutical composition comprising linagliptin and long-acting basal insulin |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| TR201010683A1 (en) * | 2010-12-21 | 2012-07-23 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Vildagliptin formulations. |
| AR085689A1 (en) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITIONS OF METFORMIN, LINAGLIPTINE AND AN SGLT-2 INHIBITOR |
| HUE043540T2 (en) | 2011-07-15 | 2019-08-28 | Boehringer Ingelheim Int | Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes |
| EA201490556A1 (en) * | 2011-09-07 | 2014-08-29 | Сановел Илач Санайи Ве Тиджарет Аноним Ширкети | COMPOSITIONS OF DPP-4 INHIBITOR |
| WO2013077824A1 (en) * | 2011-11-23 | 2013-05-30 | Mahmut Bilgic | Preparation process for a formulation comprising metformin |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2014102715A1 (en) | 2012-12-24 | 2014-07-03 | Ranbaxy Laboratories Limited | Pharmaceutical compositions comprising a biguanide and a low dose antidiabetic agent |
| MX2015008427A (en) | 2012-12-27 | 2015-10-22 | Zentiva Saglik Ürünleri San Ve Tic A S | Dry granulation process for producing tablet compositions of metformin and compositions thereof. |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| PT2981271T (en) | 2013-04-05 | 2019-02-19 | Boehringer Ingelheim Int | Therapeutic uses of empagliflozin |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN113181161A (en) | 2013-04-18 | 2021-07-30 | 勃林格殷格翰国际有限公司 | Pharmaceutical compositions, methods of treatment and uses thereof |
| WO2014184742A1 (en) | 2013-05-13 | 2014-11-20 | Ranbaxy Laboratories Limited | Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent |
| JP5922310B2 (en) * | 2013-07-25 | 2016-05-24 | 株式会社三和化学研究所 | Pharmaceutical formulation |
| CN104546779A (en) * | 2013-10-14 | 2015-04-29 | 深圳海王药业有限公司 | Sildenafil citrate tablet with high medicine loading and preparation method thereof |
| EP3086781B1 (en) * | 2013-12-23 | 2023-09-13 | KRKA, d.d., Novo mesto | Pharmaceutical composition of dpp-iv inhibitor in combination with metformin |
| CN103735544B (en) * | 2014-02-14 | 2015-08-19 | 南京华威医药科技开发有限公司 | A kind of preparation technology of vildagliptin/metformin hydrochloride compound preparation |
| ES2950384T3 (en) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Medical use of a DPP-4 inhibitor |
| CN103845326B (en) * | 2014-03-24 | 2017-07-07 | 江苏奥赛康药业股份有限公司 | Compound of vildagliptin and melbine and preparation method thereof |
| CN105582008A (en) * | 2014-11-14 | 2016-05-18 | 北京赛林泰医药技术有限公司 | Composition containing vildagliptin and metformin and preparation method of composition |
| RU2585378C1 (en) * | 2014-11-28 | 2016-05-27 | Дмитрий Сергеевич Титов | Solid dosage form for oral administration containing combination of vildagliptin and gliquidone |
| KR102496851B1 (en) * | 2015-04-10 | 2023-02-08 | 제이더블유중외제약 주식회사 | Pharmaceutical composition comprising anagliptin or a pharmaceutically acceptable salt thereof, and metformin or a pharmaceutically acceptable salt thereof and preparation method thereof |
| WO2017060861A2 (en) * | 2015-10-07 | 2017-04-13 | Steerlife India Private Limited | Rapidly disintegrating tablet compositions of dpp-iv inhibitors with low mineral content |
| CN105769796B (en) * | 2016-05-04 | 2019-06-04 | 杭州百诚医药科技股份有限公司 | A kind of pharmaceutical preparation and preparation method thereof containing vildagliptin and Metformin hydrochloride |
| BR112018072401A2 (en) | 2016-06-10 | 2019-02-19 | Boehringer Ingelheim International Gmbh | combinations of linagliptin and metformin |
| CN106432026A (en) * | 2016-09-12 | 2017-02-22 | 重庆医科大学 | Compound with potential therapeutic activity on diabetes |
| CN106421794A (en) * | 2016-09-27 | 2017-02-22 | 黑龙江珍宝岛药业股份有限公司 | Drug compound for treating type II diabetes and preparation method thereof |
| TW201938147A (en) * | 2017-12-18 | 2019-10-01 | 德商拜耳廠股份有限公司 | Fixed dose combination tablet formulation of acarbose and metformin and process for producing the same |
| TR201722603A2 (en) * | 2017-12-28 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Tablet formulations comprising metformin and sitagliptin processed with hot-melt extrusion |
| KR102622198B1 (en) * | 2018-03-30 | 2024-01-09 | 한미약품 주식회사 | Solid formulation for oral administration containing vildagliptin and a process for the preparation thereof |
| WO2019219920A1 (en) | 2018-05-18 | 2019-11-21 | Galenicum Health S.L.U | Stable pharmaceutical compositions of dpp-iv inhibitors in combination with metformin in the form of immediate release tablets |
| KR102647472B1 (en) * | 2018-07-31 | 2024-03-14 | 한미약품 주식회사 | Solid composite formulation for oral administration comprising dipeptidyl peptidase-4 inhibitor and metformine, and a process for the preparation thereof |
| GR1009644B (en) * | 2018-09-25 | 2019-11-12 | Φαρματεν Α.Β.Ε.Ε. | Pharmaceutical composition comprising vildagliptin and metformin and method of preparation thereof |
| RU2712097C1 (en) * | 2018-09-28 | 2020-01-24 | Общество с ограниченной ответственностью "Необиотек" | Dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes mellitus, compounds (versions) |
| WO2020098904A1 (en) | 2018-11-12 | 2020-05-22 | Pharmaceutical Oriented Services Ltd | Dosage form containing metformin and a dipeptidyl peptidase iv inhibitor |
| KR102362342B1 (en) * | 2020-01-31 | 2022-02-14 | 주식회사 경보제약 | Composite tablet comprising vildagliptin and metformin |
| RU2727898C1 (en) * | 2020-02-25 | 2020-07-24 | Общество с ограниченной ответственностью «Необиотек» | Pharmaceutical composition based on an active substance, an inhibitor of dipeptidyl peptidase-4, for preventing the development and treatment of type 2 diabetes mellitus |
| KR20210121599A (en) * | 2020-03-30 | 2021-10-08 | 한미약품 주식회사 | A composite tablet containing sitagliptin, dapagliflozin, metformin |
| WO2022070209A1 (en) * | 2020-09-29 | 2022-04-07 | Dr. Reddy's Laboratories Limited | Biphasic release fixed dose combination formulations |
| CN114306267A (en) * | 2020-09-30 | 2022-04-12 | 深圳翰宇药业股份有限公司 | Sitagliptin and metformin tablet preparation and preparation method thereof |
| GB2599950A (en) * | 2020-10-16 | 2022-04-20 | Zentiva Ks | Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same |
| WO2022211762A1 (en) | 2021-03-29 | 2022-10-06 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | The film coated tablet of vildagliptin and metformin hydrochloride |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| US3621097A (en) * | 1970-03-30 | 1971-11-16 | Jan Marcel Didier Aron Samuel | Method and compositions for treatment of mental illness |
| DE3720757A1 (en) * | 1987-06-24 | 1989-01-05 | Bayer Ag | DHP COAT TABLET |
| IT1276130B1 (en) * | 1995-11-14 | 1997-10-27 | Gentili Ist Spa | GLIBENCLAMIDE-METFORMIN ASSOCIATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT AND THEIR USE IN THE TREATMENT OF TYPE DIABETES MELLITUS |
| DE19823831A1 (en) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | New pharmaceutical use of isoleucyl thiazolidide and its salts |
| CO5150173A1 (en) * | 1998-12-10 | 2002-04-29 | Novartis Ag | COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION |
| ES2436610T3 (en) * | 2000-01-21 | 2014-01-03 | Novartis Ag | Combinations containing dipeptidylpeptidase-IV inhibitors and antidiabetic agents |
| AU2001294192A1 (en) * | 2000-10-06 | 2002-04-22 | Takeda Chemical Industries Ltd. | Solid preparations |
| JP4848558B2 (en) * | 2001-05-08 | 2011-12-28 | トーアエイヨー株式会社 | Rapid-release tablets containing metformin hydrochloride |
| FR2824825B1 (en) * | 2001-05-15 | 2005-05-06 | Servier Lab | NOVEL ALPHA-AMINOACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| EP1646374A1 (en) * | 2003-06-16 | 2006-04-19 | Ranbaxy Laboratories, Ltd. | Extended-release tablets of metformin |
| PT1715893E (en) * | 2004-01-20 | 2009-10-20 | Novartis Pharma Ag | Direct compression formulation and process |
| MX2007004934A (en) * | 2004-10-25 | 2007-06-12 | Novartis Ag | Combination of dpp-iv inhibitor, ppar antidiabetic and metformin. |
| GT200600008A (en) * | 2005-01-18 | 2006-08-09 | FORMULATION OF DIRECT COMPRESSION AND PROCESS | |
| GT200600218A (en) * | 2005-06-10 | 2007-03-28 | FORMULATION AND PROCESS OF DIRECT COMPRESSION | |
| JOP20180109A1 (en) * | 2005-09-29 | 2019-01-30 | Novartis Ag | New Formulation |
-
2005
- 2005-09-29 JO JOP/2018/0109A patent/JOP20180109A1/en unknown
-
2006
- 2006-09-25 SG SG10201401826TA patent/SG10201401826TA/en unknown
- 2006-09-25 NZ NZ566430A patent/NZ566430A/en unknown
- 2006-09-25 MY MYPI20080608A patent/MY144975A/en unknown
- 2006-09-25 SG SG10202011759VA patent/SG10202011759VA/en unknown
- 2006-09-25 ES ES06815305T patent/ES2377572T5/en active Active
- 2006-09-25 KR KR1020137035015A patent/KR101595169B1/en active IP Right Grant
- 2006-09-25 BR BRPI0616694A patent/BRPI0616694B8/en active IP Right Grant
- 2006-09-25 JP JP2008533471A patent/JP5415762B2/en active Active
- 2006-09-25 KR KR1020087007550A patent/KR101391085B1/en active IP Right Grant
- 2006-09-25 GT GT200600426A patent/GT200600426A/en unknown
- 2006-09-25 PT PT06815305T patent/PT1948149E/en unknown
- 2006-09-25 US US12/067,346 patent/US20080227825A1/en not_active Abandoned
- 2006-09-25 DK DK06815305.5T patent/DK1948149T4/en active
- 2006-09-25 PL PL06815305.5T patent/PL1948149T5/en unknown
- 2006-09-25 RU RU2008116316A patent/RU2483716C9/en not_active IP Right Cessation
- 2006-09-25 EP EP06815305.5A patent/EP1948149B2/en active Active
- 2006-09-25 WO PCT/US2006/037198 patent/WO2007041053A2/en active Application Filing
- 2006-09-25 AU AU2006297444A patent/AU2006297444B2/en active Active
- 2006-09-25 NO NO20200301A patent/NO346101B1/en unknown
- 2006-09-25 SG SG10201809313WA patent/SG10201809313WA/en unknown
- 2006-09-25 SI SI200631255T patent/SI1948149T2/en unknown
- 2006-09-25 CN CN2006800361747A patent/CN101277688B/en active Active
- 2006-09-25 AT AT06815305T patent/ATE533481T1/en active
- 2006-09-25 SG SG201007995-2A patent/SG166802A1/en unknown
- 2006-09-25 CA CA2623011A patent/CA2623011C/en active Active
- 2006-09-27 PE PE2006001168A patent/PE20070583A1/en active IP Right Grant
- 2006-09-27 AR ARP060104232A patent/AR055441A1/en not_active Application Discontinuation
- 2006-09-28 TW TW095136027A patent/TWI389685B/en active
- 2006-10-01 JO JOP/2006/0352A patent/JO3795B1/en active
-
2008
- 2008-02-25 ZA ZA200801773A patent/ZA200801773B/en unknown
- 2008-02-28 IL IL189856A patent/IL189856A/en active IP Right Grant
- 2008-03-27 EC EC2008008318A patent/ECSP088318A/en unknown
- 2008-03-28 TN TNP2008000146A patent/TNSN08146A1/en unknown
- 2008-04-04 MA MA30817A patent/MA29854B1/en unknown
- 2008-04-29 NO NO20082048A patent/NO344875B1/en unknown
- 2008-09-22 HK HK08110515.7A patent/HK1121372A1/en unknown
-
2010
- 2010-11-04 US US12/939,450 patent/US20110045062A1/en not_active Abandoned
-
2012
- 2012-02-02 CY CY20121100118T patent/CY1112305T1/en unknown
- 2012-09-04 US US13/602,735 patent/US20130052239A1/en not_active Abandoned
-
2013
- 2013-07-12 JP JP2013146163A patent/JP2013241429A/en not_active Withdrawn
-
2014
- 2014-01-06 PH PH12014500051A patent/PH12014500051A1/en unknown
- 2014-06-05 US US14/296,660 patent/US20140287040A1/en not_active Abandoned
-
2015
- 2015-10-09 JP JP2015201008A patent/JP6270793B2/en active Active
-
2017
- 2017-10-18 JP JP2017202104A patent/JP2018052945A/en not_active Withdrawn
-
2019
- 2019-03-08 JP JP2019042906A patent/JP2019131567A/en not_active Withdrawn
-
2020
- 2020-09-09 JP JP2020151616A patent/JP7194153B2/en active Active
-
2022
- 2022-04-12 JP JP2022065829A patent/JP2022106763A/en active Pending
-
2023
- 2023-11-13 JP JP2023193231A patent/JP2024028702A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009510068A5 (en) | ||
| JP2009545560A5 (en) | ||
| CN103550165B (en) | A kind of pharmaceutical composition and preparation method thereof containing razaxaban | |
| ES2768349T3 (en) | Pharmaceutical preparation comprising a phenylalanine derivative | |
| JP2005524658A5 (en) | ||
| CN102448445A (en) | Orally disintegrating coated tablet | |
| RU2008116316A (en) | NEW COMPOSITION | |
| EP2793866B2 (en) | Bilayer tablet comprising benazepril hydrochloride and pimobendan | |
| CA2566931A1 (en) | Tablets exhibiting reduced drug release variability | |
| EP3120871A1 (en) | Solid dispersion | |
| EP2207534B1 (en) | Mechanical protective layer for solid dosage forms | |
| JP2022177014A (en) | Solid pharmaceutical compositions for treating hcv | |
| CN102688210A (en) | Lurasidone medicine composition and preparation method | |
| CA2797042A1 (en) | Fingolimod in the form of a solid solution | |
| CN104739809B (en) | Film of water-insoluble drug of high drug load and preparation method thereof can be provided | |
| CN101854921B (en) | Pharmaceutical formulations for oral administration of PPI | |
| JP2013523834A5 (en) | ||
| Awasthi et al. | Fast disintegrating drug delivery systems: A review with special emphasis on fast disintegrating tablets | |
| CN105267150A (en) | Method for preparing rivaroxaban solid composition | |
| JP6805699B2 (en) | Pharmaceutical compositions, methods for producing pharmaceutical compositions, and methods for improving the stability of amorphous materials. | |
| JPH0797325A (en) | Stable solid pharmaceutical and its production | |
| ES2377473B1 (en) | ENERGY PELLETS OF DULOXETINE. | |
| EP3305282A2 (en) | Composition of pranlukast-containing solid preparation with improved bioavailability and method for preparing same | |
| PT1499278E (en) | IMMEDIATE RELEASE PHARMACEUTICAL FORM FOR COMPOSITION OF TIBOLONE POLYMER | |
| US20150238615A1 (en) | Denaturants for sympathomimetic amines |